Protective effects of bezafibrate against elaidic acid-induced accumulation of lipid droplets in monocytic cells

Curr Res Transl Med. 2017 Jan-Mar;65(1):20-30. doi: 10.1016/j.retram.2016.08.001. Epub 2016 Sep 28.

Abstract

Some factors related to diet, such as trans fatty acids (TFA), are known to be involved in the progression of atherosclerosis in humans. Thus, the aim of our study was (i) to evaluate the effects of three dietary free fatty acids (FFA) (elaidic (EA), oleic (OA) and palmitic acid (PA)) on U937 human monocytes, and (ii) to study the eventual benefits of bezafibrate (BZF), a pan-agonist for PPAR isoforms (α, γ and δ) in U937 cells treated with FFA. Morphologic and functional changes were investigated by microscopic and flow cytometric methods. Cellular lipid content, lipid droplets and FA composition were identified and studied. All analyses were also realized in association with or without BZF. Contrary to OA and PA, EA slightly induced both propidium iodide-positive cells and mitochondrial depolarization. In addition, in contrast to OA and PA, EA induced only a slight increase in superoxide anion production. However, EA and OA promoted cytoplasmic lipid droplets accumulation. Only EA and OA significantly increased CD36 expression. It is noteworthy that BZF had a more or less pronounced protective effect against EA-, OA- and PA-induced side effects: BZF attenuated the impaired cell viability and inflammatory response, decreased superoxide anion production and prevented the accumulation of neutral and polar lipids. The effects were less pronounced with OA and PA than with EA. Altogether, our data revealed a benefit of BZF on the side effects induced especially with EA. It may thus be of interest in preventing the early stages of atherosclerotic plaque formation.

Keywords: Bezafibrate; Elaidic acid; Lipid droplets; Oleic acid; Palmitic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bezafibrate / pharmacology*
  • Case-Control Studies
  • Coronary Disease / blood
  • Coronary Disease / metabolism
  • Coronary Disease / pathology
  • Cytoprotection / drug effects*
  • Foam Cells / drug effects
  • Foam Cells / metabolism
  • Humans
  • Lipid Droplets / drug effects*
  • Lipid Droplets / metabolism
  • Monocytes / drug effects*
  • Monocytes / metabolism
  • Oleic Acids / adverse effects*
  • Oleic Acids / blood
  • Plaque, Atherosclerotic / chemically induced*
  • Plaque, Atherosclerotic / metabolism
  • Plaque, Atherosclerotic / prevention & control*
  • U937 Cells

Substances

  • Oleic Acids
  • elaidic acid
  • Bezafibrate